Zhejiang Jingxin Company Profile

What is the competitive landscape for ZHEJIANG JINGXIN

ZHEJIANG JINGXIN has four approved drugs.

Summary for Zhejiang Jingxin

US Patents:	0
Tradenames:	4
Ingredients:	4
NDAs:	4

Drugs and US Patents for Zhejiang Jingxin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zhejiang Jingxin	LEVETIRACETAM	levetiracetam	TABLET;ORAL	091491-004	Dec 14, 2010	AB	RX	No	No
Zhejiang Jingxin	ROSUVASTATIN CALCIUM	rosuvastatin calcium	TABLET;ORAL	206513-003	Mar 1, 2019	AB	RX	No	No
Zhejiang Jingxin	LEVETIRACETAM	levetiracetam	TABLET;ORAL	091491-003	Dec 14, 2010	AB	RX	No	No
Zhejiang Jingxin	ROSUVASTATIN CALCIUM	rosuvastatin calcium	TABLET;ORAL	206513-002	Mar 1, 2019	AB	RX	No	No
Zhejiang Jingxin	TICAGRELOR	ticagrelor	TABLET;ORAL	219006-001	Mar 24, 2026	AB	RX	No	No
Zhejiang Jingxin	ROSUVASTATIN CALCIUM	rosuvastatin calcium	TABLET;ORAL	206513-001	Mar 1, 2019	AB	RX	No	No
Zhejiang Jingxin	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	TABLET;ORAL	209946-001	Jul 15, 2020	AB	RX	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Zhejiang
• Zhejiang Hisun Pharm
• Zhejiang Jingxin
• Zhejiang Jiuzhou
• Zhejiang Jutai Pharm
• Zhejiang Novus
• Zhejiang Novus Pharm

Last updated: June 10, 2026

Zhejiang Jingxin competitive landscape analysis: market position, strengths, and strategic insights

Zhejiang Jingxin is a China-based pharmaceutical and chemical manufacturing group that operates across multiple dosage forms and industrial intermediates, with a commercial footprint concentrated in domestic supply and OEM/contract manufacturing. Its competitive posture is shaped by (1) broad manufacturing capability and scale, (2) process and cost discipline typical of Chinese generics and intermediates players, and (3) the company’s reliance on product portfolio breadth rather than a single blockbuster patent moat. In a market where regulatory scrutiny and patent enforcement govern launch timing, Jingxin’s most material advantages tend to be execution speed (CMC scale-up and tech transfer) and supply reliability, while its main strategic risk is exposure to competitor pricing pressure and IP barriers in higher-value therapeutic niches.

The competitive landscape for Zhejiang Jingxin, and the ability to underwrite defensible growth, depends on a narrow set of verifiable facts: named regulatory submissions in China’s NMPA system, mapped approvals by strength/formulation, and a patent estate tied to specific marketed drugs. Those hard data are not provided in the prompt, so this analysis cannot be completed accurately.